Table 3.
Multidomain trials | Study | Potential intervention effect modifiers | Analyses | Results |
---|---|---|---|---|
FINGER | Rosenberg et al., 2018 [27] | Sex, age, education, socioeconomic status, cognition, cardiovascular factors, and cardiovascular comorbidity at baseline | Pre-specified | No significant differences in cognitive intervention benefits by sex, age, education, socioeconomic status, cognition, cardiovascular factors, and cardiovascular comorbidity. |
Solomon et al., 2018 [28] | APOE ε4 allele | Pre-specified |
Intervention benefits were not significantly different between carriers and non-carriers. Clear benefit in APOE4 carriers in stratified analyses. |
|
Deckers et al., 2020 [29] | LIBRA index at baseline | Post hoc | Participants with a higher LIBRA index at baseline had overall less cognitive improvement over time, but this effect was not different between the intervention and control groups. | |
Sindi et al., 2017 [30] | Leukocyte telomere length | Post hoc | More pronounced cognitive intervention benefits in individuals with shorter baseline leukocyte telomere length (higher-risk individuals). | |
Stephen et al., 2019 [31] | Brain volumes and cortical thickness | Post hoc | More pronounced cognitive intervention effects in individuals with higher brain baseline cortical thickness and volumes. | |
MAPT | Andrieu et al., 2017 [19] | Cognition and functioning level at baseline | Pre-specified | No significant differences in intervention effects. |
Andrieu et al., 2017 [19] | APOE ε4 allele | Post.hoc | Intervention effects were not significantly different between carriers and non-carriers. | |
Tabue-Teguo et al., 2018 [32] | Frailty status | Post hoc | Beneficial effects of multidomain intervention and n3 PUFA supplementation on cognition did not differ between frail and non-frail participants. | |
Delrieu et al., 2019 [33] | Amyloid status | Post hoc | Multidomain intervention alone or in combination with omega-3 fatty acids was associated with improved primary cognitive outcomes in individuals with positive amyloid status. | |
Chhetri et al., 2018 [34] | CAIDE score ≥ 6 points | Post hoc | High-risk subjects for dementia screened with CAIDE dementia score might benefit more from multidomain intervention. | |
preDIVA | Moll van Charante et al., 2016 [18] | Participants free from cardiovascular disease | Pre-specified | Participants with a history free from cardiovascular disease who were adherent to the intervention had a significantly lower risk of dementia compared to the control group. |
Moll van Charante et al., 2016 [18] | Untreated hypertension at baseline | Pre-specified | Participants with untreated hypertension who were adherent to the intervention had a significantly lower risk of dementia compared with the control group. | |
van Middelaar et al., 2018 [35] | LIBRA index at baseline | Post hoc | LIBRA modifiable dementia risk score did not identify a (high-)risk group in whom the multidomain intervention was effective in preventing dementia or cognitive decline. |
Subgroup analysis type (pre-specified and post hoc) was assessed from published trial protocols
APOE apolipoprotein E, CAIDE Cardiovascular Risk Factors, Aging and Dementia, FINGER Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, LIBRA LIfestyle for BRAin health, MAPT Multidomain Alzheimer Preventive Trial, preDIVA Prevention of Dementia by Intensive Vascular Care, PUFA polyunsaturated fatty acids